30.08.2013 16:01:00

Before the Bell Scans: Hologic Inc., St. Jude Medical Inc., ResMed Inc., and Navidea Biopharmaceuticals Inc.

LONDON, August 30, 2013 /PRNewswire/ --

The U.S. equity market advanced on Thursday, August 29, 2013. All three benchmark indexes edged higher, with the Dow Jones Industrial Average gaining 0.11%, S&P 500 gaining 0.20%, and the NASDAQ Composite advancing 0.75%. Shares in the medical appliances and equipment companies ended on a mixed note as the broader market edged higher. The major movers in the sector included Hologic Inc. (NASDAQ: HOLX), St. Jude Medical Inc. (NYSE: STJ), ResMed Inc. (NYSE: RMD), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). All these companies are tracked by AAAResearchReports.com. Free technical research on HOLX, STJ, RMD, and NAVB can be downloaded upon sign up at:

http://www.aaaresearchreports.com/register/  

On Thursday, Hologic Inc.'s stock closed 0.60% lower at $21.57 after oscillating between $21.39 and $21.72. A total of 1.85 million shares were traded, which is less than its daily average volume of 3.26 million. The company's stock has gained 6.94% in last three months, outperforming the S&P 500 which has lost 0.62% during the same period. Moreover, the company's shares are trading above their 50-day and 200-day moving averages. Sign up today to read free research report on HOLX at:

http://www.AAAResearchReports.com/HOLX083013.pdf

Shares in St. Jude Medical Inc. fluctuated between gains and losses on Thursday before closing the day nearly flat. The company's shares traded between $50.12 and $50.93 before ending the day 0.02% lower at $50.60. A total of 0.63 million shares traded, which is below the daily average volume of 1.84 million. The company's stock has gained 14.43% in the last three months, outperforming the S&P 500 which has fallen by 0.62% during the same period. Additionally, St. Jude Medical Inc.'s stock is trading above its 50-day and 200-day moving averages. Register to download free technical analysis on STJ at:

http://www.AAAResearchReports.com/STJ083013.pdf

ResMed Inc.'s shares posted modest gains on Thursday. The company's shares traded between $47.92 and $48.46 before finishing the day 0.06% higher at $48.23. A total of 0.66 million shares were traded, which is below the daily average volume of 1.09 million. The company's shares have gained 4.51% in the last one month, outperforming the S&P 500 which has lost 2.80% during the same period. Furthermore, ResMed Inc.'s stock is currently trading above its 50-day and 200-day moving averages. A free report on RMD can be accessed by registering at:

http://www.AAAResearchReports.com/RMD083013.pdf

Shares in Navidea Biopharmaceuticals Inc. moved higher on Thursday, extending their gains from previous trading sessions. The company's shares ended the day at $2.99, up 1.01%, after oscillating between $2.91 and $3.01. A total of 0.29 million shares were traded, which is below the daily average volume of 0.68 million. The company's stock is up 26.16% in the last three months, outperforming the S&P 500 which has lost 0.62% during the same period. Additionally, Navidea Biopharmaceuticals Inc.'s stock is trading above its 50-day and 200-day moving averages. Register with AAA Research Reports and download the research on NAVB for free at:

http://www.AAAResearchReports.com/NAVB083013.pdf

EDITOR NOTES:

  • This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  • Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA ® charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  • This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  • If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  • For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  • Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

  • COMPLIANCE PROCEDURE

    Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

    NOT FINANCIAL ADVICE

    Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

    NO WARRANTY OR LIABILITY ASSUMED

    Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

    www.AAAresearchreports.com

    SOURCE AAA Research Reports

    Analysen zu ResMed Inc.mehr Analysen

    Eintrag hinzufügen
    Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
    Es ist ein Fehler aufgetreten!

    Aktien in diesem Artikel

    Hologic IncShs 70,00 -2,10% Hologic IncShs
    ResMed Inc. 227,20 -2,03% ResMed Inc.